Nothing said here yet.
to join the conversation.
Janux Therapeutics has seen a steep mix of gains and setbacks in recent years, which puts fresh attention on a basic question for you as a shareholder or potential buyer.
Janux Therapeutics (JANX) has drawn fresh attention after recent trading left the stock at $18.15, with returns over the past month, past 3 months, and year telling very different stories for investors.
Janux Therapeutics has seen a sharp mix of gains and setbacks in recent years, which puts a spotlight on whether its current share price lines up with what its sales can support.
Janux Therapeutics has recently dosed the first patient in its Phase 1 trial evaluating JANX013 in combination with JANX007 for metastatic castration-resistant prostate cancer, marking a new step in its clinical pipeline.
Janux Therapeutics (JANX) just hit a clinical milestone, dosing the first patient in its Phase 1 trial of JANX013 with JANX007 for metastatic castration-resistant prostate cancer. This development is sharpening investor focus on this prostate cancer platform.
Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.
In the past, Janux Therapeutics, Inc. reported second-quarter 2026 results showing a net loss of US$21.97 million, or US$0.35 per share, compared with a net loss of US$33.86 million, or US$0.55 per share, a year earlier.
Janux Therapeutics (JANX) delivered earnings and revenue surprises of -34.62% and -72.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, August 06, 2026--Janux Therapeutics, Inc.
In late June 2026, Janux Therapeutics, Inc. was removed from several Russell growth and small-cap benchmarks, including the Russell 2000 Growth, 2500 Growth, Small Cap Comp Growth, 3000E Growth, and 3000 Growth indexes.